Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today

Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics today

Editas Medicine EVP, Chief Medical Officer Daniel Ory Files Initial Beneficial Ownership Statement

Editas Grants New CMO Daniel Ory Stock Options for 950,000 Shares at USD 3.03 Each

Press Release: Editas Medicine Reports Inducement Grants to New Chief Medical Officer

JonesTrading Remains a Buy on Beam Therapeutics (BEAM)

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints

Beam Therapeutics falls -12.7%

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Intellia Rises After FDA Grants Fast-Track Status to Its Treatment for Rare Disease

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Intellia Therapeutics Shares up 4.9% Premarket After FDA Accepts to Fast-Track Co's Treatment for a Rare Swelling Disorder

Intellia Therapeutics announces FDA acceptance of lonvo-z BLA

Intellia Says FDA Accepts Lonvo-Z BLA for Hereditary Angioedema, Grants Priority Review

Intellia Therapeutics, - FDA Accepts Bla for Lonvo-Z and Grants Priority Review with Pdufa Date March 10, 2027

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-Z) for Hereditary Angioedema (Hae)

Intellia Therapeutics, - FDA not Planning to Hold Advisory Committee for Lonvo-Z Application

Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Editas Medicine Appoints Dan Ory, M.d., as Chief Medical Officer